Testing
Lp(a) testing rates remain low (1.9%) and therapy intensification is incomplete in the cvMOBIUS-2 registry (Circ Popul Health Outcomes 2026)
Original title: Lipoprotein (a) Testing and Changes in Lipid-Lowering Therapy in Patients With ASCVD: Findings From the cvMOBIUS-2 Registry
This registry study of 1 948 540 patients with atherosclerotic cardiovascular disease found that only 36 410 (1.9%) underwent Lp(a) testing between 2021 and 2024, rising from 0.2% to 0.8% annually. Among tested patients, 31.1% had elevated Lp(a) (>=125 nmol/L or >=50 mg/dL). Female sex and non-Hispanic Black patients were less likely to be tested but had higher odds of elevated levels. Therapy intensification for LDL-C>=55 mg/dL increased with higher Lp(a) levels, yet over half of patients with Lp(a)>=200 nmol/L or >=80 mg/dL received no treatment change. The study underscores a persistent gap between guideline recommendations and real-world testing and treatment practices.
Original abstract
Background: Although the effectiveness of Lp(a) (lipoprotein[a])-lowering therapies remains under study, lipid guidelines now recommend Lp(a) testing in all adults to identify individuals who need more aggressive risk factor modification. Therefore, we evaluate contemporary patterns of Lp(a) testing and the impact of testing on LDL-C (low-density lipoprotein cholesterol) management.
Methods: Electronic health record patient data from 13 US health systems from January 1, 2021 to January 1, 2025, were utilized to assess the annual proportion of patients with atherosclerotic cardiovascular disease who underwent Lp(a) testing. Multivariable logistic regression was used to identify factors associated with (1) Lp(a) testing and (2) high Lp(a) (≥125 nmol/L or ≥50 mg/dL). Changes in lipid-lowering therapy after Lp(a) testing were evaluated, stratified by Lp(a) level.
Results: Among 1 948 540 patients with atherosclerotic cardiovascular disease (44% female sex; mean age, 70.9±12.8 years), 36 410 (1.9%) had an Lp(a) test. Testing increased slightly over time but remained low: from 0.2% in 2021 to 0.8% in 2024. Among tested patients, 31.1% had elevated Lp(a). Although female sex (odds ratio, 0.95 [95% CI, 0.93-0.98]) and non-Hispanic Black patients (0.79 [95% CI, 0.76-0.82]) were less likely to undergo testing, these groups had higher odds of elevated Lp(a) (1.19 [95% CI, 1.14-1.25] and 2.83 [95% CI, 2.63-3.05], respectively). Intensification of lipid-lowering therapy in those with LDL-C≥55 mg/dL increased with higher Lp(a) levels: 32.7% with Lp(a) 125 to <200 nmol or 50 to <80 mg/dL, and 38.2% with Lp(a)≥200 nmol or ≥80 mg/dL had lipid-lowering therapy intensification (Ptrend<0.001).
Conclusions: Lp(a) testing remains low despite guideline recommendations. Although those with elevated Lp(a) were more likely to undergo lipid-lowering therapy intensification, over half of those with Lp(a)≥200 nmol/L or ≥ 80 mg/dL had no change in therapy. These results highlight a significant gap in clinical care and an opportunity to improve the use of Lp(a) testing to guide LDL-C management.
epidemiologyguidelinestestingtherapy
Summary written by lp-a.org from the published abstract; figures as published. Page updated 6 September 2026. Methods.